Here's what we'll cover
Here's what we'll cover
If you've lost significant weight on a GLP-1 medication and are worried about keeping it off, or about losing muscle in the process, you're not alone. A Colorado biotech company called Enveda is working on a drug that could eventually address both problems. But before you get too excited, here's what the early data actually shows and what it means for your care right now.
What Enveda Is Actually Testing
Enveda is a Colorado-based biotech that focuses on plant-derived compounds and metabolic pathways. The drug they're studying is designed to activate some of the same biological signals that exercise triggers in the body, particularly those related to fat metabolism and muscle preservation.
The company has shared preliminary results from a Phase 1 clinical trial. Phase 1 trials are primarily designed to test safety and tolerability in a small number of people, not to prove that a drug works at scale. So while these results are genuinely interesting, they represent a very early step in a long process.
The compound appears to interact with leptin signaling. Leptin is a hormone produced by fat cells that tells your brain you've had enough to eat and plays a role in regulating energy balance. When people lose a lot of weight, leptin levels drop, and the body often fights back by increasing hunger and slowing metabolism. This is one reason weight regain after stopping GLP-1 medications is so common.
Enveda's drug appears aimed at keeping that metabolic dial from swinging too far back in the wrong direction.
Why Muscle Loss Matters So Much on GLP-1 Medications
GLP-1 receptor agonists like Ozempic (semaglutide) and Mounjaro (tirzepatide) are highly effective for weight loss. But they don't distinguish perfectly between fat loss and muscle loss. When you eat significantly less, your body can break down muscle tissue for energy alongside fat.
Clinical trials for Wegovy (semaglutide 2.4 mg) showed that roughly 30 to 40 percent of weight lost could come from lean mass, including muscle. For Mounjaro and its obesity-approved counterpart Zepbound, the muscle loss proportion appears somewhat lower, but it's still a genuine concern.
Why Muscle Loss Has Real Consequences
Losing muscle isn't just a cosmetic issue. Muscle tissue is metabolically active, meaning it burns calories even at rest. Less muscle means a lower resting metabolic rate, which makes it harder to maintain weight loss long term. It also affects strength, mobility, and bone density, especially in older adults.
Doctors and researchers have been looking for ways to protect muscle during GLP-1-driven weight loss, and Enveda's compound is one of the more novel approaches to surface publicly.
How the Compound Works Differently From GLP-1 Medications
GLP-1 medications work primarily by slowing digestion, reducing appetite, and improving insulin response. They don't directly target the exercise-related pathways in muscle tissue.
Enveda's compound takes a different angle. It appears to activate pathways associated with mitochondrial function and metabolic flexibility, which are things that typically improve with regular physical activity. That's where the "exercise in a pill" framing comes from, though the company's researchers are pushing back on that label.
And that pushback is worth taking seriously. Exercise does far more than activate metabolic pathways. It strengthens the heart, improves mood, builds bone density, and reduces inflammation in ways that no single compound is likely to replicate fully. Calling any drug "exercise in a pill" sets expectations that the science can't currently meet.
What Enveda seems to be targeting is more specific: can this compound help the body hold onto muscle and maintain a healthier metabolic rate during and after significant weight loss? That's a narrower, more realistic goal, and it's a meaningful one.
Where This Drug Stands in the Development Timeline
It's important to be direct about this: Enveda's drug is years away from being available to patients, if it ever reaches that point.
Here's a rough overview of where it sits relative to FDA approval:
| Trial Phase | Primary Goal | Typical Duration | Enveda Status |
|---|---|---|---|
| Phase 1 | Safety and dosing in small groups | 1-2 years | Preliminary results reported |
| Phase 2 | Efficacy signals in larger groups | 2-3 years | Not yet started |
| Phase 3 | Large-scale efficacy and safety confirmation | 3-5 years | Not yet started |
| FDA Review | Regulatory approval decision | 1-2 years | Not yet started |
Even in an optimistic scenario, a drug like this would not reach pharmacies before the early 2030s. Many compounds that look promising in Phase 1 never make it to approval.
What the Weight Regain Problem Actually Looks Like
To understand why a drug like Enveda's is being developed, it helps to understand the scale of the weight regain problem that GLP-1 users face.
A landmark study published in the journal Diabetes, Obesity and Metabolism followed participants who had taken semaglutide for 68 weeks and then stopped. Within one year of stopping, participants regained an average of two-thirds of the weight they had lost. Their metabolic markers, including blood pressure and blood sugar control, also returned toward baseline.
This isn't a personal failure. It reflects how powerfully the body defends its previous weight set point, using hunger hormones, metabolic slowdown, and behavioral drives. Leptin is a central player in that defense system, which is exactly why Enveda is targeting it.
The challenge of weight maintenance after stopping GLP-1 medications is one of the biggest open questions in obesity medicine right now. Some clinicians advise staying on GLP-1 medications long term. Others are exploring rotating patients to lower doses. Enveda's approach, if it works, could eventually offer a third option.
What GLP-1 Users Should Actually Do Right Now
While Enveda's research is worth watching, it shouldn't change your current plan. Here's what the evidence supports today for people on GLP-1 medications who want to protect their muscle mass and improve long-term outcomes.
Prioritize Resistance Training
Resistance exercise, meaning lifting weights, using resistance bands, or doing bodyweight exercises, is the most effective intervention available right now for preserving muscle during weight loss. Even two to three sessions per week can make a measurable difference. This applies whether you're on semaglutide, tirzepatide, or any other GLP-1 medication.
Eat Enough Protein
Protein is the raw material your body uses to build and maintain muscle. Most guidelines for people losing weight on GLP-1 medications suggest aiming for at least 1.2 to 1.6 grams of protein per kilogram of body weight per day. Because GLP-1 medications reduce appetite significantly, many users find it harder to hit this target without intentional planning.
Don't Stop Your Medication Without a Plan
If you're considering stopping a GLP-1 medication, do it in conversation with your prescriber, not independently. Your provider can help you build a tapering plan, adjust your diet, and set up support structures that reduce the risk of rapid weight regain. You can compare provider options that offer ongoing support at Best Providers.
Talk to Your Doctor About Long-Term Strategy
Ask your prescriber directly: "What's the plan for maintaining my results long term?" If you don't have a clear answer, that's a conversation worth having. Some patients do well on maintenance doses of GLP-1 medications. Others may eventually transition off. The right answer depends on your individual metabolic profile, health history, and goals.
Questions to Ask Your Doctor About Muscle Loss and Weight Maintenance
Many patients don't know to ask about muscle loss specifically during GLP-1 treatment. Here are questions that can help start a useful conversation with your provider.
- Am I losing muscle mass along with fat, and is there a way to monitor this during treatment?
- Should I be doing resistance training, and if so, how much and what type?
- Am I getting enough protein given my current appetite and intake?
- What does my long-term plan look like if I want to eventually reduce or stop this medication?
- Are there any newer approaches to weight maintenance I should know about?
These questions apply whether you're taking Ozempic, Wegovy, Mounjaro, or any compounded GLP-1 alternative. If cost is a factor in your treatment decisions, the GLP-1 Coupons page is worth checking before your next refill.
No waiting list. No insurance needed.
Frequently Asked Questions
What is Enveda's exercise pill and how does it work?
Enveda is a Colorado biotech company testing a compound that activates some of the same metabolic pathways triggered by physical exercise, particularly those tied to mitochondrial function and leptin signaling. The goal is to help people maintain weight loss and preserve muscle mass, especially after stopping GLP-1 medications. It's in early Phase 1 trials and is not available to patients.
Can you really replace exercise with a pill?
No current drug can fully replicate what exercise does for the body. Exercise affects cardiovascular health, bone density, mood, inflammation, and much more than any single compound can match. Enveda's drug targets specific metabolic pathways, not the full spectrum of exercise benefits, and the company's own researchers caution against calling it "exercise in a pill."
How much muscle do you lose on GLP-1 medications like Ozempic or Wegovy?
Studies suggest that roughly 30 to 40 percent of weight lost on semaglutide-based medications like Wegovy may come from lean mass, including muscle. Tirzepatide-based drugs like Mounjaro appear to have a somewhat better muscle-sparing profile, but muscle loss is still a concern with all GLP-1 medications.
What can I do right now to protect my muscle while on a GLP-1 medication?
The two most evidence-supported strategies are resistance training and adequate protein intake. Aim for at least two to three resistance exercise sessions per week and try to consume 1.2 to 1.6 grams of protein per kilogram of body weight daily. Talk to your doctor or a registered dietitian for a plan tailored to your situation.
What happens when you stop taking a GLP-1 medication?
Most people regain a significant portion of their lost weight after stopping GLP-1 medications. One major study found that participants regained about two-thirds of their lost weight within one year of stopping semaglutide. This happens because the body's hunger hormones and metabolic rate adjust back toward baseline. Having a maintenance plan before stopping is essential.
When will Enveda's drug be available to patients?
Even under optimistic projections, the drug is likely many years from FDA approval. It has only completed early Phase 1 safety testing. Phase 2 and Phase 3 trials, followed by regulatory review, would need to follow, putting a realistic availability timeline in the early 2030s at the earliest, and only if all phases succeed.
The Bottom Line for GLP-1 Patients
Enveda's early results are genuinely interesting from a scientific standpoint. Targeting leptin pathways to preserve muscle and sustain metabolic rate is a smart approach to one of the hardest problems in obesity medicine: what happens after the weight comes off.
But interesting early science and available treatment are very different things. If you are currently on a GLP-1 medication or considering starting one, Enveda's compound is not a factor in your decision right now. What matters is what you can do today.
That means working with a provider who understands long-term weight management, not just short-term prescribing. It means asking about muscle preservation, protein intake, and exercise as part of your overall plan. And it means having an honest conversation about what happens if and when you eventually want to reduce or stop your medication.
The weight loss landscape is evolving quickly. New compounds, new delivery methods, and new combinations are emerging every year. Some will pan out. Many won't. The best thing you can do is stay informed without getting swept up in early-stage hype, and keep your care grounded in what the evidence supports today.
What to Do Next
If you're researching GLP-1 options, comparing providers, or looking for ways to reduce out-of-pocket costs, GLP-1.com has tools to help. You can browse and compare Best Providers based on cost, telehealth access, and support quality. You can also check the GLP-1 Coupons page for current savings on branded medications like Ozempic, Wegovy, and Mounjaro.
As always, any change to your medication or treatment approach should happen in partnership with your physician or a qualified prescriber.